158 related articles for article (PubMed ID: 34551907)
1. Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.
Zavras PD; Shastri A; Goldfinger M; Verma AK; Saunthararajah Y
Clin Cancer Res; 2021 Dec; 27(24):6653-6661. PubMed ID: 34551907
[TBL] [Abstract][Full Text] [Related]
2. Management of myelodysplastic syndromes after failure of response to hypomethylating agents.
Gil-Perez A; Montalban-Bravo G
Ther Adv Hematol; 2019; 10():2040620719847059. PubMed ID: 31156799
[TBL] [Abstract][Full Text] [Related]
3. Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy.
Abbas HA; Alaniz Z; Mackay S; Cyr M; Zhou J; Issa GC; Alfayez M; Matthews J; Kornblau SM; Jabbour E; Garcia-Manero G; Konopleva M; Andreeff M; Daver N
Blood Adv; 2021 Nov; 5(22):4569-4574. PubMed ID: 34555853
[TBL] [Abstract][Full Text] [Related]
4. Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility.
Gómez-Centurión I; Oarbeascoa G; García MC; López Fresneña MC; Martínez Carreño MJ; Escudero Vilaplana V; González-Haba E; Bailén R; Dorado N; Juárez LM; Rodríguez Macías G; Font López P; Encinas C; Bastos-Oreiro M; Anguita J; Sanjurjo M; Díez-Martin JL; Kwon M
Int J Hematol; 2022 Jan; 115(1):61-68. PubMed ID: 34553338
[TBL] [Abstract][Full Text] [Related]
5. Novel agents for myelodysplastic syndromes.
Xu K; Hansen E
J Oncol Pharm Pract; 2021 Dec; 27(8):1982-1992. PubMed ID: 34558354
[TBL] [Abstract][Full Text] [Related]
6. Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation.
Wang CL; Wu VC; Tu HT; Huang YT; Chen SW; Chu PH; Wen MS; Huang HL; Chang SH
J Thromb Thrombolysis; 2022 Apr; 53(3):633-645. PubMed ID: 34557973
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis.
Du Y; Li C; Yan J
Hematology; 2023 Dec; 28(1):2198098. PubMed ID: 37036307
[TBL] [Abstract][Full Text] [Related]
8. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
Dev R; Zhong LL; Zarifa A; Albittar AA; Rubin L; Liu S; Yap TA; Dalal S; Hui D; Karp DD; Tsimberidou AM; Piha-Paul SA; Ahnert JR; Fu S; Meric-Bernstam F; Naing A
Invest New Drugs; 2022 Feb; 40(1):124-133. PubMed ID: 34559346
[TBL] [Abstract][Full Text] [Related]
9. Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cluzeau T; Loschi M; Fenaux P; Komrokji R; Sallman DA
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576266
[TBL] [Abstract][Full Text] [Related]
10. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Yanagisawa T; Kimura T; Mori K; Suzuki H; Sano T; Otsuka T; Iwamoto Y; Fukuokaya W; Miyajima K; Enei Y; Sakanaka K; Matsukawa A; Onuma H; Obayashi K; Tsuzuki S; Hata K; Shimomura T; Miki J; Egawa S
Prostate; 2022 Jan; 82(1):3-12. PubMed ID: 34559410
[TBL] [Abstract][Full Text] [Related]
12. Transition from Compounded to Monotherapy Intrathecal Pain Medication Reduces Drug Costs: Retrospective Analysis of Patient Billing Data.
Scarfo KA; Leary OP; Gaudet D; Carayannopoulos AG; Grande G
Pain Physician; 2021 Sep; 24(6):489-494. PubMed ID: 34554697
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
Dai MS; Feng YH; Chen SW; Masuda N; Yau T; Chen ST; Lu YS; Yap YS; Ang PCS; Chu SC; Kwong A; Lee KS; Ow S; Kim SB; Lin J; Chung HC; Ngan R; Kok VC; Rau KM; Sangai T; Ng TY; Tseng LM; Bryce R; Bebchuk J; Chen MC; Hou MF
Breast Cancer Res Treat; 2021 Oct; 189(3):665-676. PubMed ID: 34553296
[TBL] [Abstract][Full Text] [Related]
14. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring
Meric-Bernstam F; Bahleda R; Hierro C; Sanson M; Bridgewater J; Arkenau HT; Tran B; Kelley RK; Park JO; Javle M; He Y; Benhadji KA; Goyal L
Cancer Discov; 2022 Feb; 12(2):402-415. PubMed ID: 34551969
[TBL] [Abstract][Full Text] [Related]
15. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Short NJ; Muftuoglu M; Ong F; Nasr L; Macaron W; Montalban-Bravo G; Alvarado Y; Basyal M; Daver N; Dinardo CD; Borthakur G; Jain N; Ohanian M; Jabbour E; Issa GC; Qiao W; Huang X; Kanagal-Shamanna R; Patel KP; Bose P; Ravandi F; Delumpa R; Abramova R; Garcia-Manero G; Andreeff M; Cortes J; Kantarjian H
J Hematol Oncol; 2023 Jul; 16(1):73. PubMed ID: 37422688
[TBL] [Abstract][Full Text] [Related]
16. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.
Levitz D; Saunthararajah Y; Fedorov K; Shapiro LC; Mantzaris I; Shastri A; Kornblum N; Sica RA; Shah N; Konopleva M; Gritsman K; Braunschweig I; Cooper DL; Pradhan K; Verma A; Feldman EJ; Goldfinger M
Clin Cancer Res; 2023 Aug; 29(15):2774-2780. PubMed ID: 37341641
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT.
Chen Z; Zhen S; Zhang T; Shen Y; Pang A; Yang D; Zhang R; Ma Q; He Y; Wei J; Zhai W; Chen X; Jiang E; Han M; Feng S
Front Oncol; 2023; 13():1137175. PubMed ID: 37035180
[TBL] [Abstract][Full Text] [Related]
18. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
Garcia-Manero G; Goldberg AD; Winer ES; Altman JK; Fathi AT; Odenike O; Roboz GJ; Sweet K; Miller C; Wennborg A; Hickman DK; Kanagal-Shamanna R; Kantarjian H; Lancet J; Komrokji R; Attar EC; Sallman DA
Lancet Haematol; 2023 Apr; 10(4):e272-e283. PubMed ID: 36990622
[TBL] [Abstract][Full Text] [Related]
19. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Zeidan AM; Borate U; Pollyea DA; Brunner AM; Roncolato F; Garcia JS; Filshie R; Odenike O; Watson AM; Krishnadasan R; Bajel A; Naqvi K; Zha J; Cheng WH; Zhou Y; Hoffman D; Harb JG; Potluri J; Garcia-Manero G
Am J Hematol; 2023 Feb; 98(2):272-281. PubMed ID: 36309981
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A; Darbaniyan F; Jabbour E; Montalban-Bravo G; Ohanian M; Chien K; Kadia T; Takahashi K; Masarova L; Short N; Alvarado Y; Yilmaz M; Ravandi F; Andreeff M; Kanagal-Shamanna R; Ganan-Gomez I; Colla S; Qiao W; Huang X; McCue D; Mirabella B; Kantarjian H; Garcia-Manero G
Lancet Haematol; 2022 Oct; 9(10):e756-e765. PubMed ID: 36063832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
